Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatment

@inproceedings{Yang2016PemetrexedHS,
  title={Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatment},
  author={Chih-Jen Yang and Ming-Ju Tsai and J B Hung and T. C. Liu and Shah Hwa Chou and J N Lee and Jui-Sheng hSu and Ying-Ming Tsai and Ming-Shyan Huang and Inn-Wen Chong},
  booktitle={OncoTargets and therapy},
  year={2016}
}
BACKGROUND Increased evidences show that epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors such as gefitinib could prolong progression-free survival (PFS) compared with cytotoxic chemotherapy for metastatic lung nonsquamous cell carcinoma harboring susceptible EGFR mutation, and gefitinib was served as the first-line therapy. However, acquired resistance is inevitable, but the salvage therapies are still unclear. PATIENTS AND METHODS We designed a retrospective study of the… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 27 references

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2008
View 2 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…